FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML)
Lancet, J.E., Lin, T.L., Hogge, D., Solomon, S.R., Schiller, G.J., Wieduwilt, M.J., Martin, R., Faderl, S., Chang, Y., Cortes, J.E.
Published in Hematology, Transfusion and Cell Therapy (01.11.2020)
Published in Hematology, Transfusion and Cell Therapy (01.11.2020)
Get full text
Journal Article
PB1733 OUTCOMES WITH CPX‐351 VERSUS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH‐RISK/SECONDARY AML: EXPLORATORY ANALYSIS OF A PHASE 3 STUDY
Ritchie, E.K., Lin, T.L., Stuart, R.K., Solomon, S.R., Schiller, G.J., Wieduwilt, M.J., Ryan, D.H., Ryan, R.J., Chiarella, M., Cortes, J.E.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article